How much does domestically produced Crizotinib cost after being covered by medical insurance?

Crizotinib (Crizotinib) is an oral targeted therapy drug mainly used to treat a specific type of cancer, namely tyrosine kinase fusion-positive non-small cell lung cancer (ALKpositive NSCLC) and ROS1 fusion-positive non-small cell lung cancer (ROS1positive NSCLC).

Crizotinib is currently on the market in China and is included in medical insurance. Patients can purchase it domestically, and the price is around 6,000~12,000 yuan. Since the price of medical insurance policies varies greatly across regions, please consult your local pharmacy or medical insurance bureau for specific prices. There are original and generic versions of crizotinib available abroad. The original version is mainly Pfizer’s original drug, and the price is around 11,000 yuan. Generic drugs are mainly from Bangladesh and Laos. Due to different pharmaceutical manufacturers and drug specifications, generic drugs cost around 2,700~3,000 yuan. Moreover, the ingredients of foreign original drugs and generic drugs are basically the same as those of domestic drugs.

ALKandROS1fusion-positiveNSCLC is a specific subtype of non-small cell lung cancer in which ALK or ROS1 gene is fused with other genes, resulting in abnormal ALK or ROS1 fusion protein expression. These fusion proteins activate abnormal signaling pathways in cancer cells, promoting cancer cell growth and spread.

Crizotinib, as a targeted therapy drug, blocks the abnormal proliferation of cancer cells and slows down the development of tumors by specifically inhibiting the activity of abnormal ALK or ROS1 fusion proteins.

The drug was originally developed by Pfizer (Pfizer) and was approved by the U.S. Food and Drug Administration (FDA) in 2011 under the trade nameXalkori®. Since then, crizotinib has been approved by many countries around the world and has become one of the important treatment options for patients with certain lung cancers.